Testing blood clotting in people with liver cirrhosis
Treatments studied
Part of Digestive system, Heart & circulation clinical trials.
This Phase 4 study looks at how clotting measurements relate to bleeding risk in people with liver cirrhosis who need a planned liver procedure. The study may help doctors understand what coagulation results mean when doing these procedures safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cirrhosis at University Hospital Vienna
- Your blood clotting tests are abnormal (INR above 1.5 and/or platelets below 50,000 per microliter)
- You are scheduled for one of these planned procedures: liver biopsy/needle, microwave or radiofrequency ablation, TIPS, or PTCD drain
- You can give informed consent (or have someone who can for you, if allowed by the study)
- You are age 18 or older
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to manage blood clotting around the time of a TIPS procedure in adults with cirrhosis, to see if a safer clotting strategy helps. It may be useful if you are having TIPS for a specific complication of liver disease.
This study is following people with cirrhosis to see how often they get a blood clot in the liver's main vein (portal vein) and whether using blood thinners helps. If you have cirrhosis, joining this study could help doctors learn better ways to prevent and treat these clots.
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
This study looks at blood clotting in patients with cirrhosis who are getting a TIPS—a tube placed in the liver to help blood flow. The study aims to understand how the procedure affects bleeding and clotting, which could help make it safer for people with liver disease.
This trial tests whether a pill (dabigatran) or a daily injection (enoxaparin) is better at preventing new blood clots in the liver vein for people with cirrhosis. Both are blood thinners, and the study wants to see which one is safer and more effective.
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.